Tumor-dissociated cells, examined for the presence of stemness marker CD44+/CD24-, showed higher stemness in vehicle-treated group (87.6%) compared to triple-therapy-treated tumors (48.6% for DGD and 65.2% in CGD) (Figure 6I). The gene discussed is CD24; the disease is neoplasm.